<code id='5924626E6C'></code><style id='5924626E6C'></style>
      • <acronym id='5924626E6C'></acronym>
      <center id='5924626E6C'><center id='5924626E6C'><tfoot id='5924626E6C'></tfoot></center><abbr id='5924626E6C'><dir id='5924626E6C'><tfoot id='5924626E6C'></tfoot><noframes id='5924626E6C'>
      • <optgroup id='5924626E6C'><strike id='5924626E6C'><sup id='5924626E6C'></sup></strike><code id='5924626E6C'></code></optgroup>
        5. <b id='5924626E6C'><label id='5924626E6C'><select id='5924626E6C'><dt id='5924626E6C'><span id='5924626E6C'></span></dt></select></label></b><u id='5924626E6C'></u>
          <i id='5924626E6C'><strike id='5924626E6C'><tt id='5924626E6C'><pre id='5924626E6C'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / leisure time      
           
     
           
      
          leisure time 
           
      
           
      
           
       2025-09-28 11:55:23 
   
      
           
      
           
                        
          leisure time  
          
                                   
                 
                                      author：explore   
                                        
                                      
                                      Page View：523
                                  
                                    
          
                                   
          Franklin faces
          Adobe
          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.
          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.
          advertisement
          Arch declined to comment on the new fundraising.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Woodcock on FDA’s accelerated approval and her next chapter 
                                
                            
          Next article：  
                                      
                                          How to save PrEP access — and even expand it
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles